NCT01366092View on ClinicalTrials.gov

Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

October 31, 2014

Study Completion Date

December 31, 2025

Conditions
Chronic Graft-versus-host Disease
Interventions
DRUG

Interleukin-2

Daily subcutaneous IL-2 (1 x 10\^6 IU/m\^2/day) for self-administration for 12 weeks followed by 4-week hiatus

Trial Locations (3)

02214

Dana-Farber Cancer Institute, Boston

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors

Collaborators (1)

Prometheus Laboratories
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Prometheus Laboratories

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER